4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis Cognitive Assessment, Palbociclib, Quality-of-Life Assessment - Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative | Phase 2 | Terminated | Northwestern University | 12 | 2016-08-31 | 2020-04-14 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Biomarker Analysis, Enzalutamide, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2015-06-01 | 2022-08-22 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2011-04-01 | 2017-08-30 |
Breast Neoplasms (4) · Triple Negative Breast Neoplasms (3) · Inflammatory Breast Neoplasms (1)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4)
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · Atorvastatin (1) · Capecitabine (1) · MK 2206 (1) · Mental Status and Dementia Tests (1) · PF-05280014 (1) · Trastuzumab (1) · enzalutamide (1) · palbociclib (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Northwestern University (1) · Vanderbilt-Ingram Cancer Center (1)
United States (4)
Carlos H Barcenas (1) · Cristofanilli Massimo, MD (1) · Kevin Kalinsky (1) · Vandana Abramson, MD (1)
N01CM62204 (1), P30CA013330 (1), P30CA060553 (1), P30CA068485 (1)